Neurostimulation to improve cognition in health and disease
Roi Cohen Kadosh, PhD, University of Surrey, Guilford, UK, discusses neurostimulation to improve cognition in health and disease. With abundant findings and general progress in the field, it has been possible to further understand how to provide appliable effects to improve cognition in healthy individuals and those who suffer neurological damage. Neurostimulation has been used for various neurological and psychiatric conditions; however, Prof. Cohen Kadosh describes its role in the treatment of attention deficit hyperactivity disorder (ADHD). Stimulating brain areas known to be associated with ADHD could improve the function of those individuals. Due to ease of study, most of Prof. Cohen Kadosh’s research has been conducted on healthy individuals – demonstrating increased performance in both attentional and learning tasks. Furthermore, this effect was exacerbated in individuals who demonstrated low-level attentional ability – even outperforming individuals with high-level attentional capacity after treatment. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
Roi Cohen Kadosh, PhD, University of Surrey, Guilford, UK, discusses neurostimulation to improve cognition in health and disease. With abundant findings and general progress in the field, it has been possible to further understand how to provide appliable effects to improve cognition in healthy individuals and those who suffer neurological damage. Neurostimulation has been used for various neurological and psychiatric conditions; however, Prof. Cohen Kadosh describes its role in the treatment of attention deficit hyperactivity disorder (ADHD). Stimulating brain areas known to be associated with ADHD could improve the function of those individuals. Due to ease of study, most of Prof. Cohen Kadosh’s research has been conducted on healthy individuals – demonstrating increased performance in both attentional and learning tasks. Furthermore, this effect was exacerbated in individuals who demonstrated low-level attentional ability – even outperforming individuals with high-level attentional capacity after treatment. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.
